Plain-English translation of NCT07051564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This clinical trial is testing a new treatment called for people with type 1 diabetes. The medication is made from specially prepared cells that are designed to help your body's immune system stop attacking insulin-producing cells in the pancreas. Researchers want to find out if this treatment is safe, what dose works best, and whether it can help reduce your need for insulin injections.
Type 1 diabetes occurs when the immune system mistakenly attacks the cells in your pancreas that make insulin. Current treatments focus on replacing insulin, but this medication takes a different approach by trying to calm down the immune attack itself. This trial represents a potential new way to treat the root cause of type 1 diabetes rather than just managing its symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive one injection of the experimental medication. Before and after the injection, you will have several blood tests and may wear a continuous glucose monitor to track your blood sugar levels. The study also involves visits where doctors will check your insulin use, measure your blood sugar control, and watch for any side effects. The study is small (only 12 people total) and takes place at Zibo Central Hospital in China.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Sponsor
Zibo Central Hospital
Enrollment target
~12 participants
Started
May 2025
Primary completion
December 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaoming Pang, Doctor
Zibo Central Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.